Treatment of Rosai–Dorfman disease with oral bexarotene: a case series Academic Article uri icon


MeSH Major

  • Dermoscopy
  • In Situ Hybridization, Fluorescence
  • Melanoma
  • Nevus
  • Skin Neoplasms


  • © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Background: Rosai–Dorfman disease (RDD) is a rare histiocytic proliferative disorder of unknown etiology. The skin is the most frequent extranodal site of RDD involvement and may be the only organ involved. While RDD is an indolent self-limited disease, treatment is needed in patients with extensive, persistent or progressive disease, or if cosmetic disfigurement or physical impairment significantly affects the patient. There is no specific treatment for RDD, and multiple therapeutic approaches have been described with variable success rates. Ojective: To demonstrate the clinical efficacy of oral bexarotene for RDD. Materials and methods: Descriptive retrospective case series of three patients with RDD receiving oral bexarotene. Results: Two patients had excellent response and regression of their skin lesions was achieved with long-term therapy. In the other patient, pruritus was promptly controlled while the lesions did not seem to regress and treatment was discontinued after five months. Conclusions: Our case series is the first report in the literature of the use of oral bexarotene as an effective and safe treatment for RDD.

publication date

  • July 4, 2019



  • Academic Article



  • eng

PubMed Central ID

  • PMC6526080

Digital Object Identifier (DOI)

  • 10.1080/09546634.2018.1528001

PubMed ID

  • 30244619

Additional Document Info

start page

  • 503

end page

  • 505


  • 30


  • 5